NIH Indirect Cost Suit: Federal Judge Blocks 15 Percent Research Grant Cap Nationwide

On February 21, 2025, U.S. District Judge Angel Kelley issued a nationwide preliminary injunction blocking the National Institutes of Health from replacing negotiated indirect cost rates with a uniform 15 percent cap. The order arrived eleven days after the agency had set February 10 as the effective date for the change, and six weeks after a temporary freeze on federal financial assistance had thrown grant-funded work across the country into confusion. The injunction does not decide the case; it keeps the existing rates in place while the legal challenge moves forward.

The fight is not a narrow accounting dispute. Indirect costs, which the federal government calls facilities and administrative costs, pay for the laboratory space, electricity, hazardous waste handling, compliance offices, data security, research computing, and administrative staff that make direct research charges possible. A sudden reduction in those reimbursements would fall on research universities, academic medical centers, independent institutes, and teaching hospitals that run clinical trials, maintain animal facilities, and train early-career investigators.

Those negotiated rates exist because research happens inside buildings. The federal government allows institutions to recover a portion of facilities and administrative expenses through rates that are negotiated with a cognizant agency, typically the Department of Health and Human Services or the Department of Defense. The rates vary widely: a small clinical research center may recover far less than a major academic medical center, reflecting differences in laboratory density, local utility costs, and the regulatory burden an institution carries.

The January confusion began with a memorandum from the acting director of the Office of Management and Budget on January 27. It directed agencies to pause all obligations and disbursements of federal financial assistance by 5 p.m. on January 28. A federal judge in Washington issued an administrative stay the next day, and the administration rescinded the memorandum on January 29. That did not quiet the matter. Twenty-two states and the District of Columbia obtained a temporary restraining order in Rhode Island on January 31, and the judge overseeing that case later told the administration to restore funds that remained frozen.

What the Nationwide Injunction Determines and Leaves Open

The NIH announced its uniform 15 percent rate on February 7 in supplemental guidance issued as Notice Number NOT-OD-25-068. The guidance stated that the rate would apply to new awards and to existing grants as of February 10. During the 2024 federal fiscal year, NIH obligated roughly $35 billion in grants. The agency said about $9 billion of that amount went to indirect costs, and it pointed to private foundations that commonly cap overhead between 10 and 15 percent.

A coalition of 22 state attorneys general sued the same day in the U.S. District Court for the District of Massachusetts, in a case captioned Commonwealth of Massachusetts v. National Institutes of Health. Judge Kelley issued a temporary restraining order that covered only the plaintiff states. After full briefing, she converted that order into a nationwide preliminary injunction on February 21.

A temporary restraining order is meant to hold the position for days or weeks before both sides argue more fully. A preliminary injunction, by contrast, comes after briefing and remains in effect during the litigation. The distinction matters here because the February 21 ruling is the second and more durable step, but it is still provisional in one important sense: it protects the status quo, and it does not permanently invalidate the cap.

The injunction turns on the Administrative Procedure Act. Courts may set aside agency action that is arbitrary, capricious, or contrary to law. The federal rules for facilities and administrative rates appear in 45 CFR 75.414. A negotiated rate agreement is the default mechanism the rule describes. The court's reasoning, as reported, found that the Department of Health and Human Services likely failed to supply the kind of reasoned explanation that a departure from negotiated agreements requires.

It does not follow, however, that the policy is dead. The government may appeal to the U.S. Court of Appeals for the First Circuit, or it may attempt to implement a rate change through standard notice-and-comment rulemaking. The agency could also revise its guidance and provide the analysis the court found missing.

Why the Rate Cut Drew a Legal Challenge This Quickly

The speed of the lawsuits reflects the amount at stake. Large research institutions often carry federally negotiated indirect cost rates well above 50 percent. A 15 percent cap would not change direct research costs; it would shift infrastructure costs onto institutional budgets, clinical revenue, philanthropy, or state appropriations. State attorneys general argued that the shift would immediately threaten public-sector research hospitals and laboratory networks that cannot absorb the loss.

NIH's comparison to foundation rates has drawn pushback because federal grants carry obligations that most foundation awards do not. Human subjects protections, animal welfare rules, environmental health and safety standards, conflict-of-interest reporting, and cybersecurity requirements all create administrative work. A uniform rate that ignores those costs, the plaintiffs argued, is not a cost-control measure but a restructuring of who pays for them.

The dispute also echoes a longer tension in federal science policy. Congress appropriates research dollars expecting a portion to cover infrastructure, and the executive branch negotiates the rates that determine how much infrastructure can be charged. When an agency shortens that negotiation by decree, the separation between legislative appropriation and administrative practice becomes the legal question.

What the Cap Would Have Meant in Practical Terms

An institution with a 50 percent negotiated rate would see its indirect recovery fall to 30 percent of what it had previously budgeted under a 15 percent cap. On a $1 million direct-cost base, that is the difference between recovering $500,000 and recovering $150,000. For a multi-year award tied to a building full of freezers, imaging equipment, and biosafety rooms, the shortfall cannot be absorbed by spending less on paper clips.

The costs covered by indirect rates are not discretionary extras. They include the items that keep a research enterprise compliant and safe:

• laboratory and clinical space maintenance
• electricity, heating, cooling, and water service
• hazardous chemical and biological waste disposal
• research compliance and safety offices
• data storage and cybersecurity systems
• grant administration and financial reporting staff

Each of those functions is tied to an award or a regulatory obligation. A rate cut does not make the functions disappear; it moves the expense to another budget.

How This Fits the Broader Pattern of Federal Funding Review

The NIH directive arrived while federal agencies were still assessing their portfolios after the January freeze. The original January 27 freeze is preserved in Office of Management and Budget Memorandum M-25-13. The memo itself was rescinded, but the White House said the underlying policy review would continue through executive orders. That split between the rescinded memo and the stated review created legal ambiguity, and grant offices across the country spent late January trying to learn whether ongoing federal payments would arrive.

The rate cap is therefore best understood as part of a sequence rather than an isolated decision. First came the broad pause, then the rescission and court orders over compliance, and then the attempt to change the cost structure of NIH-supported research. Each step has been tested by a different court and a different set of plaintiffs.

The Dispute's Long Tail for International Collaborators

Non-U.S. research institutions can negotiate their own rates when they receive NIH awards directly, though many participate as subrecipients or consortium partners under an American lead. In those consortium arrangements, the lead institution carries the administrative burden first. When the primary institution's facilities and administrative rate is reduced, the financial pressure sits at the top of the award, often before collaborators overseas see any change.

This is one reason the case is being watched beyond Washington. The NIH remains a central partner in global biomedical research, from infectious disease cohorts to genomics and rare disease networks. A sudden change in the cost base of American research institutions affects the speed and scale of that work, even when the legal filing is a domestic administrative law dispute.

What Funding Officers and Grant Administrators Should Watch

For the moment, institutions may continue to charge under their existing negotiated rate agreements while the case proceeds. The injunction binds the NIH and the Department of Health and Human Services. Agencies that distribute other research funds are not direct parties to this ruling, but the legal analysis may influence how they handle similar cost reforms.

The more durable question is what precedent this case sets for how the administration changes research funding terms. The episode with M-25-13 demonstrated how quickly a directive can disrupt grant-funded work. This NIH case now tests whether a substantive change to reimbursement policy can be imposed by guidance, or whether it must go through the slower process of public comment and reasoned explanation.

Researchers, finance officers, and institutional leadership will be watching the next filing deadline rather than the press release. The precedent set on February 21 is provisional, but it signals that abrupt changes to negotiated research costs will face close judicial scrutiny.

Photo by Markus Winkler on Unsplash